Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID A SAPERSTEIN

Allopathic & Osteopathic Physicians Ophthalmology

NPI
1508946625
CMS profile
203985
Location
BELLEVUE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$4,301.61

19 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,384.00 1
Food and Beverage $917.61 18

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Regeneron Healthcare Solutions, Inc. $3,848.18 8
Alcon Research LLC $181.74 1
ABBVIE INC. $122.64 3
Genentech USA, Inc. $61.32 3
Alcon Vision LLC $37.96 2
Astellas Pharma US Inc $27.69 1
Apellis Pharmaceuticals, Inc. $22.08 1

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID A SAPERSTEIN

NPI 1508946625 · CMS profile ID 203985

Allopathic & Osteopathic Physicians / Ophthalmology

BELLEVUE, WA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508946625?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID A SAPERSTEIN, NPI 1508946625, CMS profile ID 203985. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508946625?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID A SAPERSTEIN, NPI 1508946625, CMS profile ID 203985. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508946625?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID A SAPERSTEIN, NPI 1508946625, CMS profile ID 203985, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–19 of 19 matching records. This page contains 19 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1508946625?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

19 matching records · $4,301.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 19 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–19 of 19.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Genentech USA, Inc. $23.5312/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211506668 CMS
Regeneron Healthcare Solutions, Inc. $88.9212/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213032248 CMS
ABBVIE INC. $26.2712/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204060874 CMS
Regeneron Healthcare Solutions, Inc. $3,384.0011/21/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1213032246 CMS
ABBVIE INC. $71.6710/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204060867 CMS
Alcon Research LLC $181.7410/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207326539 CMS
ABBVIE INC. $24.7010/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1204060860 CMS
Regeneron Healthcare Solutions, Inc. $142.1610/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213032244 CMS
Genentech USA, Inc. $14.6209/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211506672 CMS
Astellas Pharma US Inc $27.6908/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238662389 CMS
Alcon Vision LLC $14.3208/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207510411 CMS
Alcon Vision LLC $23.6408/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207510409 CMS
Apellis Pharmaceuticals, Inc. $22.0806/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253192408 CMS
Regeneron Healthcare Solutions, Inc. $13.1005/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213032242 CMS
Regeneron Healthcare Solutions, Inc. $132.7605/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213032240 CMS
Regeneron Healthcare Solutions, Inc. $20.1905/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213032238 CMS
Genentech USA, Inc. $23.1705/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211506670 CMS
Regeneron Healthcare Solutions, Inc. $36.5203/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213032236 CMS
Regeneron Healthcare Solutions, Inc. $30.5301/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1213032234 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,404.95 7
PY2020 $4,921.42 4
PY2021 $3,310.83 5
PY2022 $3,786.65 13
PY2023 $8,227.58 15
PY2024 $23,313.03 26
PY2025 $4,301.61 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $49,152.74 22
PY2024 Principal investigator $41,747.06 19
PY2023 Principal investigator $51,577.99 16
PY2022 Principal investigator $38,480.56 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Apellis Pharmaceuticals, Inc. $23.94 12/12/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363418
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 11/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363406
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 11/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363408
Principal investigator 1 Apellis Pharmaceuticals, Inc. $4,830.00 11/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363410
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,053.00 11/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363412
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,053.00 11/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363414
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,668.00 11/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363416
Principal investigator 1 Apellis Pharmaceuticals, Inc. $150.00 09/17/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363402
Principal investigator 1 Apellis Pharmaceuticals, Inc. $40.00 09/03/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363380
Principal investigator 1 Apellis Pharmaceuticals, Inc. $80.92 09/03/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363382
Principal investigator 1 Apellis Pharmaceuticals, Inc. $20.00 08/20/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363376
Principal investigator 1 Apellis Pharmaceuticals, Inc. $94.08 08/20/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363378
Principal investigator 1 Apellis Pharmaceuticals, Inc. $2,500.00 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363384
Principal investigator 1 Apellis Pharmaceuticals, Inc. $100.00 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363386
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,000.00 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363388
Principal investigator 1 Apellis Pharmaceuticals, Inc. $3,500.00 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363390
Principal investigator 1 Apellis Pharmaceuticals, Inc. $9,000.00 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363392
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,500.00 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363394
Principal investigator 1 Apellis Pharmaceuticals, Inc. $1,000.00 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363396
Principal investigator 1 Apellis Pharmaceuticals, Inc. $686.00 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363398
Principal investigator 1 Apellis Pharmaceuticals, Inc. $262.50 08/07/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration No dispute reported 06/30/2026 1250363400
Principal investigator 1 Apellis Pharmaceuticals, Inc. $7,931.30 06/06/2025 Non-covered Recipient Entity
PACIFIC NORTHWEST RETINA PLLC
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD No dispute reported 06/30/2026 1250363404